BR9808281A - Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto - Google Patents
Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um compostoInfo
- Publication number
- BR9808281A BR9808281A BR9808281-7A BR9808281A BR9808281A BR 9808281 A BR9808281 A BR 9808281A BR 9808281 A BR9808281 A BR 9808281A BR 9808281 A BR9808281 A BR 9808281A
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- group
- compound
- compounds
- phenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002062 proliferating effect Effects 0.000 title abstract 3
- 210000000987 immune system Anatomy 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- -1 2-phenyl-1,3-dioxan-5-yl Chemical group 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 208000026278 immune system disease Diseases 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000005544 phthalimido group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS, COMPOSIçõES FARMACêUTICAS, PROCESSO PARA TRATAR DOENçAS PROLIFERATIVAS E/OU DISTúRBIOS DO SISTEMA IMUNE E PARA PREPARAR UM COMPOSTO, E, USO DE UM COMPOSTO". São descritos compostos de fórmula (I) incluindo seus sais farmaceuticamente aceitáveis em que R~ 1~ representa hidrogênio, 2-fenil-1,3-dioxan-5-ila, um grupo alquila C~ 1-6~, um grupo cicloalquila C~ 3-8~, um grupo cicloalquenila C~ 5-7~ ou um grupo alquila C~ 1-6~ (fenila opcionalmente substituída) em que os grupos alquila, cicloalquila e cicloalquenila são opcionalmente substituídos por um ou mais grupos da fórmula OR~ A~ em que R~ A~ representa H ou um grupo alquila C~ 1-6~ contanto que um grupo da fórmula OR~ A~ não esteja localizado no carbono ligado ao nitrogênio; R~ 2~ representa hidrogênio, um grupo alquila C~ 1-6~, um grupo cicloalquila C~ 3-8~, halo, hidroxi, um grupo alquila C~ 1-6~ (fenila opcionalmente substituída), fenila opcionalmente substituída ou R~ 4~; e R~ 3~ representa um grupo de fórmula (a) em que o anel de fenila é adicionalmente de forma opcional substituído e A representa NH, NHSO~ 2~, SO~ 2~NH, uma cadeia de alquileno C~ 1-4~, NHCO, NHCO~ 2~, CONH, NHCONH, CO~ 2~ ou S(O)~ p~ em que p é 0, 1 ou 2, ou A está ausente e R~ 5~ é ligado diretamente ao anel de fenila; e R~ 5~ representa fenila opcionalmente substituída e, adicionalmente, quando A está ausente R~ 5~ representa a) um grupo ftalimido opcionalmente substituído por halo ou b) um grupo pirazolilamino em que o anel de pirazol é opcionalmente substituído por um ou mais dos seguintes: hidroxi ou fenila opcionalmente substituída; R~ 4~ representa um grupo heterocíclico; que são úteis no tratamento de doenças proliferativas e desordens do sistema imunológico em mamíferos. Processos para preparar estes compostos e composições farmacêuticas contendo estes compostos são descritos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4083697P | 1997-03-19 | 1997-03-19 | |
PCT/EP1998/001357 WO1998041525A1 (en) | 1997-03-19 | 1998-03-09 | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9808281A true BR9808281A (pt) | 2000-05-16 |
Family
ID=21913242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9808281-7A BR9808281A (pt) | 1997-03-19 | 1998-03-09 | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
Country Status (23)
Country | Link |
---|---|
US (1) | US6001839A (pt) |
EP (1) | EP0970084B1 (pt) |
JP (1) | JP2001516353A (pt) |
KR (1) | KR20000076426A (pt) |
CN (1) | CN1134439C (pt) |
AT (1) | ATE242245T1 (pt) |
AU (1) | AU748884B2 (pt) |
BG (1) | BG64282B1 (pt) |
BR (1) | BR9808281A (pt) |
CA (1) | CA2283961A1 (pt) |
DE (1) | DE69815317T2 (pt) |
DK (1) | DK0970084T3 (pt) |
ES (1) | ES2202827T3 (pt) |
HU (1) | HUP0001507A3 (pt) |
ID (1) | ID24653A (pt) |
IL (1) | IL131582A0 (pt) |
NO (1) | NO313962B1 (pt) |
NZ (1) | NZ337529A (pt) |
PL (1) | PL335685A1 (pt) |
PT (1) | PT970084E (pt) |
SK (1) | SK125999A3 (pt) |
TR (1) | TR199902301T2 (pt) |
WO (1) | WO1998041525A1 (pt) |
Families Citing this family (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
CA2341409A1 (en) * | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
BR9913887A (pt) * | 1998-09-18 | 2001-10-23 | Basf Ag | Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6265403B1 (en) * | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
TR200201506T2 (tr) * | 1999-09-17 | 2002-10-21 | Abbott Gmbh & Co. Kg | Terapötik maddeler olarak kinaz inhibitörleri |
EP1212327B8 (en) | 1999-09-17 | 2004-02-25 | Abbott GmbH & Co. KG | Pyrazolopyrimidines as therapeutic agents |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
AU2001287268A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Method of identifying inhibitors of tie-2 |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
KR100403860B1 (ko) * | 2000-12-27 | 2003-11-01 | 엘지전자 주식회사 | 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법 |
TWI238824B (en) * | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
AP2003002929A0 (en) * | 2001-06-23 | 2003-12-31 | Aventis Pharma Inc | Pyrrolopyrimidines as protein kinase inhibitors |
EP1401416B1 (en) * | 2001-06-29 | 2006-10-25 | AB Science | Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd) |
US20050176687A1 (en) * | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
WO2003002105A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
WO2003003006A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
CA2452371A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
CA2452167A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
EP1425284A2 (en) * | 2001-09-11 | 2004-06-09 | Smithkline Beecham Corporation | Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
US20030225273A1 (en) * | 2002-03-21 | 2003-12-04 | Michaelides Michael R. | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors |
ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
UA80171C2 (en) * | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
US7592352B2 (en) * | 2003-05-06 | 2009-09-22 | Smithkline Beecham Corporation | Substituted thieno and furo-pyridines |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
AR045037A1 (es) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
MXPA06005578A (es) * | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
GB0403606D0 (en) * | 2004-02-18 | 2004-03-24 | Novartis Ag | Organic compounds |
CA2566160C (en) * | 2004-05-27 | 2011-01-18 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
JP2008533172A (ja) * | 2005-03-17 | 2008-08-21 | ノバルティス アクチエンゲゼルシャフト | チロシン/スレオニンキナーゼ阻害剤、特にB−RAFキナーゼ阻害剤としての、N−[3−(1−アミノ−5,6,7,8−テトラヒドロ−2,4,4b−トリアザフルオレン−9−イル)−フェニル]ベンズアミド |
RU2008117151A (ru) * | 2005-09-30 | 2009-11-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины, пригодные в качестве ингибиторов янус-киназ |
CN102936250B (zh) * | 2005-11-17 | 2014-07-09 | Osi医药有限责任公司 | 稠合双环mTOR抑制剂 |
US20070135387A1 (en) * | 2005-12-08 | 2007-06-14 | Michaelides Michael R | Inhibitors of protein kinases |
WO2007087441A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
KR101499783B1 (ko) | 2006-04-04 | 2015-03-09 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
EP2530083B1 (en) | 2006-09-22 | 2016-04-27 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
EP1969934A1 (de) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide |
SG10202107066WA (en) * | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
EP2276763A1 (en) * | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
NZ590258A (en) | 2008-07-08 | 2013-10-25 | Intellikine Llc | Kinase inhibitors and methods of use |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
AU2009305669A1 (en) * | 2008-10-16 | 2010-04-22 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
EP2663309B1 (en) | 2011-01-10 | 2017-03-15 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
FR2970967B1 (fr) | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
EA201391239A1 (ru) * | 2011-04-05 | 2014-03-31 | Пфайзер Лимитед | Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
WO2013077921A2 (en) | 2011-09-02 | 2013-05-30 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9687488B2 (en) | 2012-05-03 | 2017-06-27 | St. Louis College Of Pharmacy | Compositions and methods for increasing neurotrophic peptides |
KR20230170108A (ko) | 2012-06-04 | 2023-12-18 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
RU2015115631A (ru) | 2012-09-26 | 2016-11-20 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Модулирование ire1 |
AU2013344656A1 (en) | 2012-11-15 | 2015-06-04 | Pharmacyclics Llc | Pyrrolopyrimidine compounds as kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CN103333096A (zh) * | 2013-06-25 | 2013-10-02 | 苏州大学 | 一种化学选择性制备多功能吡咯衍生物的新方法 |
CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
HUE057734T2 (hu) | 2013-10-04 | 2022-06-28 | Infinity Pharmaceuticals Inc | Heterociklusos vegyületek és alkalmazásuk |
CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016019233A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PT3265084T (pt) | 2015-03-03 | 2024-02-13 | Pharmacyclics Llc | Formulações farmacêuticas de inibidor de tirosina cinase de bruton |
EP3334430A4 (en) * | 2015-08-13 | 2019-02-06 | San Diego State University Foundation | ATROPISOMERISM FOR INCREASED KINASE HEMMER ELECTIVITY |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
SI3472165T1 (sl) * | 2016-06-21 | 2024-02-29 | Nerviano Medical Sciences S.R.L., | N-(substituirani fenil)-sulfonamidni derivati kot inhibitorji kinaz |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN117510405A (zh) | 2017-04-18 | 2024-02-06 | 礼来公司 | 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物 |
WO2020038405A1 (zh) * | 2018-08-22 | 2020-02-27 | 江苏恒瑞医药股份有限公司 | 一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体 |
WO2020208139A1 (en) * | 2019-04-10 | 2020-10-15 | Cellestia Biotech Ag | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
SG11202111327XA (en) * | 2019-05-13 | 2021-11-29 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
CN110483523B (zh) * | 2019-08-27 | 2022-11-22 | 药雅科技(上海)有限公司 | 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途 |
AU2020336975A1 (en) * | 2019-08-29 | 2022-03-31 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
TW202233625A (zh) * | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Fgfr抑制劑及其製造及使用方法 |
US11912668B2 (en) | 2020-11-18 | 2024-02-27 | Deciphera Pharmaceuticals, Llc | GCN2 and perk kinase inhibitors and methods of use thereof |
WO2023046117A1 (en) * | 2021-09-23 | 2023-03-30 | 3H Pharmaceuticals Co., Ltd. | Fgfr inhibitors and methods of use thereof |
WO2023104035A1 (zh) * | 2021-12-06 | 2023-06-15 | 英矽智能科技(上海)有限公司 | 取代的单环或双环杂环化合物,其制法与医药上的用途 |
WO2023202625A1 (zh) * | 2022-04-20 | 2023-10-26 | 深圳福沃药业有限公司 | Fgfr2抑制剂及使用方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10501532A (ja) * | 1994-06-09 | 1998-02-10 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体拮抗物質 |
CN1046731C (zh) * | 1994-09-29 | 1999-11-24 | 诺瓦蒂斯有限公司 | 吡咯并[2,3-d]嘧啶类化合物及其应用 |
US5639757A (en) * | 1995-05-23 | 1997-06-17 | Pfizer Inc. | 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CH690773A5 (de) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
AU1794697A (en) * | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
WO1997034895A1 (de) * | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
-
1998
- 1998-03-09 PT PT98913690T patent/PT970084E/pt unknown
- 1998-03-09 IL IL13158298A patent/IL131582A0/xx unknown
- 1998-03-09 ID IDW991048A patent/ID24653A/id unknown
- 1998-03-09 DK DK98913690T patent/DK0970084T3/da active
- 1998-03-09 CN CN98805152.4A patent/CN1134439C/zh not_active Expired - Fee Related
- 1998-03-09 NZ NZ337529A patent/NZ337529A/xx unknown
- 1998-03-09 ES ES98913690T patent/ES2202827T3/es not_active Expired - Lifetime
- 1998-03-09 BR BR9808281-7A patent/BR9808281A/pt not_active IP Right Cessation
- 1998-03-09 EP EP98913690A patent/EP0970084B1/en not_active Expired - Lifetime
- 1998-03-09 TR TR1999/02301T patent/TR199902301T2/xx unknown
- 1998-03-09 CA CA002283961A patent/CA2283961A1/en not_active Abandoned
- 1998-03-09 PL PL98335685A patent/PL335685A1/xx unknown
- 1998-03-09 AU AU68293/98A patent/AU748884B2/en not_active Ceased
- 1998-03-09 AT AT98913690T patent/ATE242245T1/de active
- 1998-03-09 DE DE69815317T patent/DE69815317T2/de not_active Expired - Lifetime
- 1998-03-09 HU HU0001507A patent/HUP0001507A3/hu unknown
- 1998-03-09 JP JP54009098A patent/JP2001516353A/ja not_active Ceased
- 1998-03-09 KR KR1019997008530A patent/KR20000076426A/ko not_active Application Discontinuation
- 1998-03-09 SK SK1259-99A patent/SK125999A3/sk unknown
- 1998-03-09 WO PCT/EP1998/001357 patent/WO1998041525A1/en not_active Application Discontinuation
- 1998-03-17 US US09/042,702 patent/US6001839A/en not_active Expired - Lifetime
-
1999
- 1999-09-17 NO NO19994509A patent/NO313962B1/no not_active IP Right Cessation
- 1999-10-07 BG BG103785A patent/BG64282B1/bg unknown
Also Published As
Publication number | Publication date |
---|---|
NO994509D0 (no) | 1999-09-17 |
EP0970084B1 (en) | 2003-06-04 |
IL131582A0 (en) | 2001-01-28 |
AU748884B2 (en) | 2002-06-13 |
JP2001516353A (ja) | 2001-09-25 |
US6001839A (en) | 1999-12-14 |
ID24653A (id) | 2000-07-27 |
WO1998041525A1 (en) | 1998-09-24 |
EP0970084A1 (en) | 2000-01-12 |
BG103785A (en) | 2000-06-30 |
DE69815317D1 (de) | 2003-07-10 |
AU6829398A (en) | 1998-10-12 |
PT970084E (pt) | 2003-10-31 |
SK125999A3 (en) | 2000-05-16 |
ATE242245T1 (de) | 2003-06-15 |
DK0970084T3 (da) | 2003-09-29 |
BG64282B1 (bg) | 2004-08-31 |
PL335685A1 (en) | 2000-05-08 |
HUP0001507A2 (hu) | 2000-10-28 |
CA2283961A1 (en) | 1998-09-24 |
NO313962B1 (no) | 2003-01-06 |
KR20000076426A (ko) | 2000-12-26 |
CN1134439C (zh) | 2004-01-14 |
ES2202827T3 (es) | 2004-04-01 |
HUP0001507A3 (en) | 2002-01-28 |
TR199902301T2 (xx) | 1999-12-21 |
NO994509L (no) | 1999-09-17 |
CN1259950A (zh) | 2000-07-12 |
DE69815317T2 (de) | 2005-04-07 |
NZ337529A (en) | 2000-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9808281A (pt) | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto | |
BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
PT94925A (pt) | Processo para a preparacao de derivados de tiazol e de composicoes farmaceuticas que os contem | |
BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
PT96145A (pt) | Processo para a preparacao de novos derivados de aminoacidos e de composicoes farmaceuticas que os contem | |
BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
PT98358A (pt) | Processo para a preparacao de novos compostos pirazolopiridinicos | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
DK164937C (da) | Analogifremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt 1-alkyl-2-aminotetralinderivater til anvendelse som udgangsmateriale i fremgangsmaaden | |
BR9810021A (pt) | Derivados 9-oxima-eritromicina | |
AR019496A1 (es) | Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos | |
HUT65351A (en) | Process for preparing ethanolamine derivatives haring sympathominetic and anti-pollakiuria activity and pharmaceutical compositions containing them as active agent | |
ES2037665T3 (es) | Procedimiento para la preparacion de compuestos heterociclicos que contienen n. | |
DK562488A (da) | Farmaceutisk praeparat indeholdende polyminderivater, samt nogle af disse polyaminderivater | |
AU558261B2 (en) | Dialkylaminoalkyoxybenzylalcohol derivatives | |
DK0911026T3 (da) | Creatinderivater for astma | |
ES2058085T3 (es) | Composicion anticonvulsivante que contiene un derivado de aminoacido, y utilizacion de dicho derivado de aminoacido. | |
BR9813775A (pt) | Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular. | |
PT81314B (pt) | Processo para a obtencao de derivados de tiadiazole activos sobre o sistema nervoso central | |
EA200200292A1 (ru) | Производные гигромицина | |
EA200001028A1 (ru) | Производные 2"-деоксигигромицина | |
DE69327077D1 (de) | Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen | |
BR9806902A (pt) | Composto, formulação farmacêutica, uso de um composto, e processos para produzir um composto e uma formulação farmacêutica. | |
SE8303719D0 (sv) | Novel eburnane oxime derivatives and process for preparing same | |
ES2061579T3 (es) | Compuestos cefem y procedimientos para su preparacion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: ABBOTT GMBH & CO KG. (DE) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007. |